USA

The acquisition centers on anitocabtagene autoleucel, known as anito-cel, an investigational CAR-T cell therapy targeting multiple myeloma.

At the heart of this collaboration sits Ribo’s GalSTAR platform, a specialized system designed to help develop RNA interference therapeutics that target disease-causing genes in liver conditions.

The new San Diego facility will function as a critical node in Novartis’s integrated global research network, connecting seamlessly with existing research hubs in Basel, Switzerland, and Cambridge, Massachusetts.

The partnership centers on incorporating Diagnoly’s Fetoly platform into GE HealthCare’s established Voluson women’s health ultrasound systems, marking a significant advancement in prenatal diagnostic technology.

Once the transaction successfully closes, the combined company plans to operate under the PrimeGen US name or through a successor entity.

The deal centers on one of SanegeneBio’s innovative RNAi programs and grants Genentech exclusive worldwide rights to develop and bring the treatment to market.

The divestment positions Halo to focus on expanding into more complex drug-product manufacturing services while strengthening its presence in the sterile CDMO market.

This new facility marks Lilly’s fourth major U.S. manufacturing project in recent years and adds to its broader domestic expansion strategy.

Through this acquisition, Mirum gains worldwide rights to brelovitug, a monoclonal antibody that has advanced to Phase III clinical development.

BMS will pay up to USD850 million, structured as USD50 million in upfront and near-term payments combined with USD800 million in regulatory, development, and milestone-based payouts.